Chemomab Therapeutics Ltd.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filer
State of Incorporation
Israel
Country
Israel
Business Address
KIRYAT ATIDIM, BUILDING 7, TEL AVIV, ,
Mailing Address
KIRYAT ATIDIM, BUILDING 7, TEL AVIV, ,
Phone
972-77-331-0156
Fiscal Year End
1231
EIN
813676773
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 3 Initial insider ownership report | March 31, 2026 | View on SEC |
| 3 Initial insider ownership report | March 31, 2026 | View on SEC |
| 20-F Foreign company annual report | March 23, 2026 | View on SEC |
| 6-K Foreign company current report | March 20, 2026 | View on SEC |
| 6-K Foreign company current report | March 19, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 10, 2026 | View on SEC |
| 6-K Foreign company current report | November 21, 2025 | View on SEC |
| 6-K Foreign company current report | August 22, 2025 | View on SEC |
| 6-K Foreign company current report | August 14, 2025 | View on SEC |
Annual Reports
20-F
March 23, 2026
- Clinical-stage biotech focused on developing CM-101 for inflammatory and fibrotic diseases, including PSC and SSc.
- Actively advancing CM-101 through clinical trials, representing a high-potential therapeutic area.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.